title: Nuclear medicine for photodynamic therapy in cancer: Planning, monitoring and nuclear PDT.
abstract: Photodynamic therapy (PDT) is a modality with promising results for the treatment of various cancers. PDT is increasingly included in the standard of care for different pathologies. This therapy relies on the effects of light delivered to photosensitized cells. At different stages of delivery, PDT requires imaging to plan, evaluate and monitor treatment. The contribution of molecular imaging in this context is important and continues to increase. In this article, we review the contribution of nuclear medicine imaging in oncology to PDT for planning and therapeutic monitoring purposes. Several solutions have been proposed to plan PDT from nuclear medicine imaging. For instance, photosensitizer biodistribution has been evaluated with a radiolabeled photosensitizer or with conventional radiopharmaceuticals on positron emission tomography. The effects of PDT delivery have also been explored with specific SPECT or PET radiopharmaceuticals to evaluate the effects on cells (apoptosis, necrosis, proliferation, metabolism) or vascular damage. Finally, the synergy between photosensitizers and radiopharmaceuticals has been studied considering the Cerenkov effect to activate photosensitized cells.
authors.affiliation: Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000 Lille, France; CHU Lille, Nuclear Medicine Department, F-59000 Lille, France.
authors.forename: Dris
authors.initials: D
authors.lastname: Kharroubi Lakouas
authors.affiliation: Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000 Lille, France; CHU Lille, Nuclear Medicine Department, F-59000 Lille, France.
authors.forename: Damien
authors.initials: D
authors.lastname: Huglo
authors.affiliation: Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000 Lille, France.
authors.forename: Serge
authors.initials: S
authors.lastname: Mordon
authors.affiliation: Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000 Lille, France; CHU Lille, Nuclear Medicine Department, F-59000 Lille, France. Electronic address: m-vermandel@chru-lille.fr.
authors.forename: Maximilien
authors.initials: M
authors.lastname: Vermandel
mesh_terms: D000818:Animals; D019317:Evidence-Based Medicine; D006801:Humans; D057054:Molecular Imaging / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed / Q000379:methods*
chemical_list: D017319:Photosensitizing Agents
keywords: 5-Aminolevulinic acid; Oncology; PET; PPIX; Photodynamic therapy; SPECT